Brand vs. Compounded GLP-1 Cost: 2026 Price Guide (U.S.)

What the cost comparison actually compares

FDA says a drug may be compounded for a patient who cannot be treated with an FDA-approved medication, such as when a different form or ingredient is needed; that is a patient-need explanation, not proof of equivalence to a branded product. [S12]

The phrase “compounded GLP-1 cost” is not one standardized price field. It can describe a branded product’s self-pay offer, a savings-card amount, a pharmacy cash price, or a vendor’s bundled telehealth quote. Those lanes can include different products, doses, quantities, services, and eligibility rules. The first move is to label the lane before comparing the number. [S4][S6][S8]

A fair comparison asks what the buyer receives for the stated period. It also asks what the number does not establish. A price is not a finding about clinical appropriateness, product quality, or personal eligibility. FDA states that compounded drugs are not approved by the agency and are not verified for safety, effectiveness, or quality before marketing. [S1][S2][S3]

Treat the lowest headline number as one transaction description, not the “real” cost, and do not treat every higher number as waste. The numbers may be describing different transactions.

Current branded GLP-1 price anchors

Brand price pages are useful anchors because they define the product and the conditions attached to the offer. They are not universal quotes. NovoCare says Wegovy self-pay pricing varies by dose, defines one month for one tablet offer as one bottle of 30 tablets, and lists eligibility and restriction language. [S4]

NovoCare’s current page lists $199 per month for new patients using its Wegovy savings offer or NovoCare Pharmacy for 0.25 mg and 0.5 mg, with the offer limited to two monthly fills through December 31, 2026; it then states $349 per month for listed Wegovy doses and $399 for Wegovy HD 7.2 mg. The same page lists $149 for each month of 1.5 mg and 4 mg, with the 4 mg offer available only until August 31, 2026, then $199 per month for 4 mg. Eligibility and restrictions apply. These figures are date- and terms-bound, not a permanent brand price. [S4]

NovoCare’s current Ozempic savings page lists $199 per month for the first two months for new patients. It states that the $199 offer covers 0.25 mg and 0.5 mg for two monthly fills through December 31, 2026, then $349 for 0.25, 0.5, or 1 mg and $499 for 2 mg; eligibility, restrictions, and one-month package definitions apply. [S11]

Walgreens publishes a different kind of comparison page. It says treatment with a GLP-1 medication can be as low as $149 per month for self-paying patients, while select medication pricing requires a third-party savings card. The same page lists regular one-month Zepbound KwikPen or vial prices by dose from $299 to $699. [S6]

The practical lesson is to record the product, dose, package, date checked, offer type, and eligibility language beside the price. “Brand cost” without those fields is too vague to compare.

For a related oral-product lane, see the Wegovy pills cost guide. For the broader alternatives landscape, see the Ozempic alternatives guide.

Compounded GLP-1 price examples

PlexusDx reports a range of $129 to $309 per month depending on formulation, concentration, and delivery method. It also describes an all-inclusive price that, according to the vendor, includes an online provider visit, prescription, compounded semaglutide, and shipping. [S8]

PlexusDx separately reports $189 per month for compounded semaglutide month-to-month, from $149 per month on a six-month plan, and $289 for compounded tirzepatide. Those figures are vendor-reported examples from a commercial page. They should not be silently converted into an industry-wide price range or treated as proof that two products are equivalent. [S8]

GoodRx adds a different caution: compounded semaglutide may appear in dosage forms beyond injections, and there may be no FDA-approved version of that dosage form to use as a reference. It also says compounded medications are not always covered by insurance and may require out-of-pocket payment. [S7]

The table is useful for understanding how offers are framed, not for selecting a product. PlexusDx attributes its reported range to formulation, concentration, and delivery method and describes an all-inclusive provider/shipping bundle; FDA says compounded drugs are not FDA-approved. [S8][S1][S2]

Why monthly numbers are easy to misread

“Per month” is only meaningful when the period and contents are defined. NovoCare’s cited tablet offer defines one month as one bottle of 30 tablets. PlexusDx says its range depends on formulation, concentration, and delivery method. Those statements show why a headline number should be treated as an index into the terms, not the conclusion. [S4][S8]

PlexusDx says its all-inclusive price includes an online provider visit, prescription, compounded semaglutide, and shipping, and it attributes its reported range to formulation, concentration, and delivery method. Those are page-level descriptions of that vendor’s offer, not a causal rule for every compounded quote. [S8]

A branded pharmacy page can show a different price lane: Walgreens lists one-month Zepbound KwikPen or vial prices by dose, while NovoCare’s offers define their own dose, quantity, eligibility, and date terms. Neither direction proves better value without the same comparison fields. [S4][S6]

Do not use a dose, concentration, or milligram figure to infer clinical equivalence. A price comparison can document what a page says; it cannot turn two different products into the same product or provide instructions for using either one. [S1][S2][S7]

The online GLP-1 program cost guide can help separate program fees from medication pricing. The GLP-1 cost calculator should only be used when its inputs keep product, quantity, payer lane, and evidence date visible.

Approval, quality, and safety boundaries

FDA says compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness, or quality before they are marketed. FDA also distinguishes compounded drugs from approved generic drugs. That is a regulatory-status statement, not a claim that every compounded product will have the same outcome or that every branded purchase is automatically appropriate. [S2]

FDA’s current GLP-1 statement says unapproved versions do not undergo the agency’s review for safety, effectiveness, and quality before marketing. It says compounded drugs should only be used when a patient’s medical needs cannot be met by an FDA-approved drug, and it advises obtaining a prescription from a doctor and filling it at a state-licensed pharmacy. [S1]

FDA also reports adverse-event reports that may be related to dosing errors involving compounded injectable semaglutide. Brown Health similarly warns that differences in concentrations and vials can increase dosing-error risk. This article does not provide dosing instructions; the point is that price research must not be separated from product labeling, prescribing, and pharmacy verification. [S1][S9]

Keep the evidence categories separate: FDA sources establish approval and quality boundaries; brand pages establish their own offers; vendor pages report their own prices; a price comparison article should not merge those categories.

A quote-comparison checklist

Before comparing a branded price with a compounded quote, write down the answer to each item below. If a field is missing, mark it “not stated” rather than guessing.

This checklist is intentionally administrative. It does not diagnose, recommend a medicine, tell a reader how to use a product, or predict a personal outcome.

1. What is the exact product and form named on the page?
2. Is the product branded or compounded, and does the page clearly say so?
3. What quantity and time period does “monthly” represent?
4. Are provider evaluation, prescription handling, shipping, supplies, and follow-up included?
5. Which pharmacy or dispensing entity is identified?
6. What restrictions apply to the stated price, including introductory terms, cadence, payer type, or government-program exclusions?
7. Are taxes, fees, memberships, cancellations, or price changes described?
8. Is the quote insurance, self-pay, a savings card, or an out-of-pocket vendor offer?
9. Does the route require a prescription and identify a state-licensed pharmacy? FDA advises patients to obtain a prescription and use a state-licensed pharmacy. [S1]
10. Are you comparing price terms only, without inferring safety, quality, or clinical equivalence? FDA says compounded drugs are not FDA-approved. [S1][S2]

Methodology

We searched the exact query “compounded GLP-1 cost” in Firecrawl and preserved the ten returned positions, including the duplicate at position 10. Direct source captures were then saved for current FDA boundaries, brand pricing pages, a secondary compounded explainer, a vendor price page, and a health-system safety explainer. Search-only observations were closed as discovery evidence and were not used for load-bearing claims.

The article separates four evidence classes: FDA regulatory and safety statements, manufacturer or pharmacy price terms, vendor-reported offer examples, and secondary educational context. Quotes are stored in the packet ledger with quote hashes. No checkout, enrollment, payer lookup, provider mutation, affiliate route, publication, deployment, GSC submission, email, or spend action was performed.

Bottom line

Compounded GLP-1 cost can look lower than branded self-pay pricing, but a headline monthly number is not a complete comparison. Record the product, form, quantity, cadence, provider service, shipping, pharmacy, eligibility, and terms before evaluating the price. Brand pages and vendor pages describe their own offers; they do not create one universal market price. [S4][S6][S8]

The most important boundary is regulatory and evidentiary. FDA says compounded drugs are not FDA-approved and are not verified by the agency for safety, effectiveness, or quality before marketing. A low price cannot establish equivalence or safety, and this guide cannot replace a clinician, plan, or licensed pharmacy’s current answer. [S1][S2]

Update policy

Checked date: August 16, 2026. Recheck brand price pages whenever dose pricing, savings eligibility, package definitions, taxes, fees, or offer end dates change. Recheck FDA pages when approval, compounding, quality, shortage, or safety guidance changes. Recheck vendor examples before quoting them because vendor-reported prices and included services can change. [S1][S4][S5][S8]